Home > Insider Trading > Filing (0001601830-24-000047)

Filing Details

Accession Number:: 0001601830-24-000047
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2024-05-03 18:24:24
Reporting Period:: 2024-05-01

Accepted Time:: 2024-05-03 18:24:24
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1601830	Recursion Pharmaceuticals Inc.	RXRX	Biological Products, (No Disgnostic Substances) (2836)	464099738

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1856369	Christopher Gibson	C/O Recursion Pharmaceuticals 41 S. Rio Grande Street Salt Lake City UT 84101	Chief Executive Officer	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Class A Common Stock	Disposition	2024-05-01	25,000	$0.00	913,524	No	4	G	Direct
Class A Common Stock	Disposition	2024-05-01	50,000	$7.73	863,524	No	4	S	Direct
Class A Common Stock	Disposition	2024-05-02	28,704	$8.47	834,820	No	4	S	Direct
Class A Common Stock	Acquisiton	2024-05-02	21,296	$0.00	856,116	No	4	C	Direct
Class A Common Stock	Disposition	2024-05-02	21,296	$8.47	834,820	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	G	Direct
No	4	S	Direct
No	4	S	Direct
No	4	C	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Class A Common Stock	Class B Common Stock	Disposition	2024-05-02	21,296	$0.00	21,296	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
6,426,700			No	4	C	Direct

Reported Derivative Holdings

Show Other Fields >>

Sec. Name	Sec. Type	Price	Date	Expiration Date	Remaning Holdings	Nature of Ownership
Class A Common Stock	Class B Common Stock	$0.00			486,000	Indirect
Class A Common Stock	Class B Common Stock	$0.00			388,000	Indirect
Class A Common Stock	Class B Common Stock	$0.00			67,875	Indirect
Class A Common Stock	Stock Option (Right to Buy)	$8.55		2033-02-01	813,600	Direct
Class A Common Stock	Stock Option (Right to Buy)	$2.48		2030-12-30	312,500	Direct
Class A Common Stock	Stock Option (Right to Buy)	$11.40		2032-02-04	399,002	Direct
Class A Common Stock	Stock Option (Right to Buy)	$11.40	2022-02-04	2032-02-04	5,436	Direct
Class A Common Stock	Stock Option (Right to Buy)	$10.09		2034-02-09	666,898	Direct

Expiration Date	Remaning Holdings	Nature of Ownership
	486,000	Indirect
	388,000	Indirect
	67,875	Indirect
2033-02-01	813,600	Direct
2030-12-30	312,500	Direct
2032-02-04	399,002	Direct
2032-02-04	5,436	Direct
2034-02-09	666,898	Direct

Footnotes

This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 27, 2023
Represents the automatic conversion of Class B Common Stock into Class A Common Stock in connection with a bona-fide gift of shares by the Reporting Person.
Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date.
This number of shares represents the correct number of shares of Class B shares held by the Reporting person as of the date of this report, correcting an error in his running total from 2023.
The shares are held by LAHWRAN-3 LLC, of which the Reporting Person is a member and a manager.
The shares are held by LAHWRAN-4 LLC, of which the Reporting Person is a member and a manager.
The shares are held by the Gibson Family Trust, of which the Reporting Person serves as Trustee.
The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
The option, originally for 1,500,000 shares, vested as to one forty-eighth (1/48th) of the shares subject to the option on January 31, 2021, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
The option, originally for 416,350 shares, vested as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
The option vests as to one forty-eighth (1/48th) of the original 666,898 shares subject to the option on March 1, 2024, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.